Design Therapeutics(DSGN) - 2025 Q4 - Annual Results

Exhibit 99.1 Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing Clinical Execution Carlsbad, Calif., March 9, 2026 - Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic disea ...